Cell Therapy: The Final Frontier for Treatment of Neurological Diseases

被引:19
|
作者
Dutta, Susmita [2 ]
Singh, Gurbind [1 ]
Sreejith, Sailaja [1 ]
Mamidi, Murali Krishna [1 ,3 ]
Husin, Juani Mazmin [1 ]
Datta, Indrani [3 ]
Pal, Rajarshi [3 ]
Das, Anjan Kumar [1 ]
机构
[1] Stempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, Malaysia
[2] Int Med Univ, Kuala Lumpur 57000, Malaysia
[3] Manipal Univ, Manipal Inst Regenerat Med, Bangalore, Karnataka, India
关键词
Cell transplantation and clinical trials; Neural differentiation; Neurorepair; Stem cells; MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; NEURAL PROGENITOR CELLS; BONE-MARROW; DIRECT CONVERSION; NEURONAL DIFFERENTIATION; DOPAMINERGIC-NEURONS; CORD BLOOD; EXPERIMENTAL STROKE; HUMAN FIBROBLASTS;
D O I
10.1111/cns.12027
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Neurodegenerative diseases are devastating because they cause increasing loss of cognitive and physical functions and affect an estimated 1 billion individuals worldwide. Unfortunately, no drugs are currently available to halt their progression, except a few that are largely inadequate. This mandates the search of new treatments for these progressively degenerative diseases. Neural stem cells (NSCs) have been successfully isolated, propagated, and characterized from the adult brains of mammals, including humans. The confirmation that neurogenesis occurs in the adult brain via NSCs opens up fresh avenues for treating neurological problems. The proof-of-concept studies demonstrating the neural differentiation capacity of stem cells both in vitro and in vivo have raised widespread enthusiasm toward cell-based interventions. It is anticipated that cell-based neurogenic drugs may reverse or compensate for deficits associated with neurological diseases. The increasing interest of the private sector in using human stem cells in therapeutics is evidenced by launching of several collaborative clinical research activities between Pharma giants and research institutions or small start-up companies. In this review, we discuss the major developments that have taken place in this field to position stem cells as a prospective candidate drug for the treatment of neurological disorders.
引用
收藏
页码:5 / 11
页数:7
相关论文
共 50 条
  • [31] INTRAVENOUS IMMUNOGLOBULIN THERAPY IN NEUROLOGICAL DISEASES
    Cojocaru, Manole
    Cojocaru, Inimioara Mihaela
    Negres, Simona
    Popa, Florian
    Purcarea, Victor Lorin
    Arsene, Andreea Letitia
    FARMACIA, 2011, 59 (06) : 737 - 741
  • [32] The final frontier?
    Allan, K
    IEE REVIEW, 2004, 50 (06): : 24 - 25
  • [33] THE FINAL FRONTIER
    MARKS, LU
    ARTFORUM, 1993, 32 (04): : 83 - 84
  • [34] The final frontier
    Reider, B
    AMERICAN JOURNAL OF SPORTS MEDICINE, 2003, 31 (01): : 1 - 1
  • [35] Hyperbaric oxygen therapy in neurological diseases
    Ahmad, Faiz M. H.
    Sankhla, Charulata S.
    NEUROLOGY INDIA, 2019, 67 (03) : 655 - 656
  • [36] Editorial: Mitochondrial therapy in neurological diseases
    Chang, Jui-Chih
    Chen, Linyi
    Chang, Chuang-Rung
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2022, 15
  • [37] The final frontier
    Clarke, AC
    FORBES, 1998, : 54 - +
  • [38] The Final Frontier
    Loudis, Jessica
    NATION, 2022, 314 (11) : 40 - +
  • [39] Final frontier
    Spiegel, Rory
    Johnston, Michelle
    Ercleve, Tor
    Nickson, Christopher P.
    EMERGENCY MEDICINE AUSTRALASIA, 2015, 27 (02) : 92 - 94
  • [40] The final frontier?
    Buchanan, Mark
    NATURE PHYSICS, 2008, 4 (06) : 431 - 431